Health-related quality of life in Chinese multiple myeloma patients treated with daratumumab-based regimens in real world: Exploratory analysis of the MMY4032
Exploratory analysis shows stability in health-related quality of life amidst efficacy in multiple myeloma patients, highlighting the impact of daratumumab treatment.
Key Points
This study investigates the health-related quality of life in Chinese patients receiving daratumumab-based therapies for multiple myeloma.
Multicenter, non-interventional, observational registry study
Assessed health-related quality of life using EORTC QLQ-C30 and EQ-5D-5L VAS
Included patients aged ≥18 with ≤3 prior lines of therapy
Median follow-up duration was 23.7 months
LS mean changes from baseline in EQ-5D-5L VAS showed an increasing trend until Month 18
Improvements in role functioning and fatigue were observed at certain time points